Yale SPORE in Lung Cancer News

A listing of recent publications by Yale Cancer Center researchers and clinicians in the first quarter of 2024

Dr. Katerina Politi on Yale Cancer Answers.

A new, highly sensitive test for a cancer biomarker could allow more lung cancer patients to benefit from a recently FDA-approved chemotherapy.

According to a new report, cancer deaths are continuing to go down, but new cases among young adults are increasing.

The AACR Cancer Progress Report 2024: Inspiring Science | Fueling Progress | Revolutionizing Care

Researchers for now don’t have enough data to say whether ivonescimab improved overall survival — the gold standard outcome in cancer research — though they plan to report those results in the future. That’s the key piece of data Summit still needs for this therapy to change clinical practice, said Roy Herbst, chief of medical oncology at Yale Cancer Center. “This is a triple,” said Herbst, describing the results in baseball terms. “The only reason it’s not a home run is they haven’t shown survival benefit yet. But this is very impressive.”

A member of the Yale School of Medicine faculty since 2010, Politi co-leads the Cancer Signaling Networks Research Program at the Yale Cancer Center.

The world's first mRNA lung cancer vaccine is now in clinical trials. Yale Cancer Center deputy director Dr. Roy Herbst discussed the new developments of the trial with WWLP 22News.

Dr. Roy Herbst, deputy director of Yale Cancer Center, discusses what researchers are hoping to accomplish with upcoming clinical trials.